Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2038

Annual patent cliff calendar for 2038 — US pharmaceutical patents by expiration date.

Patents
1,509

Quick answer

1,509 indexed pharmaceutical patents have expiration dates in 2038. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10087143

    Pyridone amides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10087169

    Bicyclic PKM2 activators

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10087172

    Compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10087229

    Peptide compound

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10087210

    Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

    Ionis Pharmaceuticals, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10087211

    Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10087230

    Murine anti-NY-ESO-1 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10087232

    Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

    Protalix Ltd. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10085968

    Multicyclic compounds and methods of use thereof

    PGI Drug Discovery LLC · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10087252

    Methods and compositions for treating and preventing disease associated with αvβ5 integrin

    The Regents of the University of California · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10087413

    Thin film cell encapsulation devices

    The Regents of the University of California · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10085964

    Ultrapure tetrahydrocannabinol-11-oic acids

    Corbus Pharmaceuticals, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10085935

    Bee venom composition with effects of protecting and beautifying lip

    SOUTH CHINA SEA INSTITUTE OF OCEANOLOGY, CHINESE ACADEMY OF SCIENCES · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10085986

    Pyrimidinone compounds and their use

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10087240

    DNA antibody constructs and method of using same

    Inovio Pharmaceuticals, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10087181

    Compound as WNT signaling inhibitor, composition, and use thereof

    Curegenix, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10086114

    Antimicrobial solutions with enhanced stability

    The Board of Regents of the University of Texas System · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10085974

    Dosage and formulation

    Almirall, S.A. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10086061

    Combination purified inactivated vaccine for flaviviruses

    The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10087444

    MicroRNA composition for the treatment of neuroblastoma

    The Board of Regents of the University of Texas System · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10093742

    Multispecific GITR-binding fusion proteins and methods of use thereof

    Inhibrx, Inc. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10092504

    Use of cellular extracts for skin rejuvenation

    REGENICS AS · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10092580

    Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders

    The Regents of the University of California · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10092596

    Tungstate treatment of the dysbiosis associated with gastrointestinal inflammation

    The Regents of the University of California · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10093664

    Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10093684

    Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10093708

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10093745

    Anti-CSPG4 fusions with interferon for the treatment of malignancy

    The Regents of the University of California · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10092559

    Abuse resistant pharmaceutical compositions

    RECRO GAINESVILLE LLC · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10092512

    Compositions and methods of making brittle-matrix particles through blister pack freezing

    The Board of Regents of the University of Texas System · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10092583

    Imidazopyridines Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10092538

    Suppositories comprising cannabinoids

    AXIM BIOTECHNOLOGIES. INC. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10092593

    Citrate-rich calcium-magnesium supplement and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10092598

    Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

    RegenLab USA LLC · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10092637

    Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10092656

    Protease inhibitors having enhanced features

    Nektar Therapeutics · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10092736

    Device and method for dispensing a drug

    Demira, Inc. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10093629

    Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10093654

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10093668

    Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)

    Northwestern University · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10093641

    Process for making beraprost

    United Therapeutics Corporation · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10093676

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10093694

    Compounds for treating eye disorders or diseases

    The Regents of the University of California · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10093710

    Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10093698

    Peptide having efficacy for remedying hypopigmentation and inhibiting adipogenesis, and use of same

    CAREGEN CO., LTD. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10093686

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10093790

    Three-dimensional cellulose molded body, method for the production thereof and use of the same

    LENZING AKTIENGESELLSCHAFT · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10094836

    SLCO1B3 genotype

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2038?

1,509 published patents in our USPTO index have expiration dates falling in calendar year 2038.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.